Maximum amount of contingent payments under collaborative arrangement.

No definition available.

Name:	rigl_CollaborativeArrangementPotentialPayments
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of collaborative arrangement upfront payment.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of potential milestone payment obligations.

+ References

No definition available.

+ Details

Name:	rigl_PotentialMilestonePaymentObligations
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percentage of potential tiered royalties.

+ References

No definition available.

+ Details

Name:	rigl_PotentialTieredRoyaltyPercentage
Namespace Prefix:	rigl_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

+ Details

Name:	us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479908/805-50-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction cost incurred as part of consideration transferred in asset acquisition.

+ References

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.

+ References

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Name:	us-gaap_AssetAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.

+ References

+ Details

Name:	us-gaap_AssetAcquisitionPriceOfAcquisitionExpected
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1

+ Details

Name:	us-gaap_IntangibleAssetsNetIncludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rigl_GavretoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rigl_RezlidhiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_FdaApprovalAndFirstCommercialSaleOfProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_FirstCommercialSaleMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_FirstAnniversaryOfClosingDateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

IN-LICENSING AND ACQUISITION - Narrative (Details) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 22, 2024	Jul. 31, 2024	Dec. 31, 2022	Jul. 31, 2022	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2022	Dec. 31, 2024
Asset Acquisition [Line Items]
Acquisition-related liabilities					$ 5,000		$ 5,000
Acquisition-related liabilities										$ 5,000
Research and development					6,821	$ 5,540	15,257	$ 11,566
Intangible asset					25,924		$ 25,924			27,100
Forma
Asset Acquisition [Line Items]
Upfront fee				$ 2,000
Research and development									$ 2,000
Forma \| Commercial milestones
Asset Acquisition [Line Items]
Potential payments				165,500
Forma \| Development and regulatory milestones
Asset Acquisition [Line Items]
Potential payments				$ 67,500
Forma \| Achievement of certain near-term regulatory milestone
Asset Acquisition [Line Items]
Research and development			$ 2,500
GAVRETO (pralsetinib)
Asset Acquisition [Line Items]
Intangible assets, estimated useful life							12 years
REZLIDHIA
Asset Acquisition [Line Items]
Intangible assets, estimated useful life							14 years
REZLIDHIA \| Forma \| FDA approval and first commercial sale of product
Asset Acquisition [Line Items]
Intangible asset			$ 15,000						$ 15,000
Blueprint \| GAVRETO (pralsetinib)
Asset Acquisition [Line Items]
Asset acquisition, expected price	$ 15,000
Acquisition-related liabilities					$ 5,000		$ 5,000			$ 5,000
Purchase consideration	15,400
Acquisition payment	15,000	$ 10,000
Transaction costs	$ 400
Blueprint \| GAVRETO (pralsetinib) \| Minimum
Asset Acquisition [Line Items]
Potential tiered royalties (as a percentage)	10.00%
Blueprint \| GAVRETO (pralsetinib) \| Maximum
Asset Acquisition [Line Items]
Potential tiered royalties (as a percentage)	30.00%
Blueprint \| GAVRETO (pralsetinib) \| First commercial sale
Asset Acquisition [Line Items]
Asset acquisition, expected price	$ 10,000
Blueprint \| GAVRETO (pralsetinib) \| First anniversary of the closing date
Asset Acquisition [Line Items]
Asset acquisition, expected price	5,000
Blueprint \| GAVRETO (pralsetinib) \| Commercial milestones
Asset Acquisition [Line Items]
Potential milestone payments	97,500
Blueprint \| GAVRETO (pralsetinib) \| Regulatory milestones
Asset Acquisition [Line Items]
Potential milestone payments	$ 5,000